Control of disease activity and tumor size after introduction of pegvisomant in a lanreotide-resistant acromegalic patient
{{output}}
We report on a 30-year-old female acromegalic patient treated with the growth hormone (GH) receptor antagonist pegvisomant at a low dose after the failure of long-acting lanreotide, neurosurgery and radiotherapy treatment to restore IGF-1 levels. The combinati... ...
